Dilon Launches US FDA Cleared Clinical Trial for Use of MarginProbe® in Breast Cancer Surgery

[vc_row][vc_column][vc_column_text]Dilon Devices, Ltd. today announced the launch of a pivotal clinical trial of the MarginProbe™ intraoperative, real-time, positive margin detection system, following U.S. Food and Drug Administration (FDA) investigational device exemption (IDE) approval of its protocol during breast cancer surgery. With the FDA IDE approval in place, Dune is launching a nationwide U.S. clinical trial…

Read More

Randomized, Controlled Multicenter Trial Demonstrates Safety and Clinical Benefit, Significant Reduction in Repeat Surgeries Enabled by Dune’s MarginProbe®

[vc_row][vc_column][vc_column_text]Company Opens US Office to Spearhead North American Operations Caesarea, Israel-Jan. 7, 2008 – Dilon Devices announces significant new clinical developments surrounding the company’s novel breast cancer assessment probe, currently in investigational use. Results from a recent randomized clinical trial in 11 medical centers in Israel have underscored the safety and clinical benefit of the…

Read More